Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,562
datasets available to search
ShareScore release 0.9.0
Dataset results
2,562 results for “SARS CoV 2”
SARS-CoV-2 spike protein complexes and their contacts
<p>This archive contains protein complex structures containing SARS-CoV-2 spike protein as well as derived data.</p>
Data for: A catalytic model for SARS-CoV-2 reinfections: Performing simulation-based validation and extending the model to include nth infections
<p>For code and more details see: </p> <ul> <li><code>inf_for_sbv.RDS</code> - simluated timeseries of primary infections used in the simulation-based validation of reinfections. </li> <li><code>inf_for_sbv_third.RDS</code> - simluated timeseries of primary infections used in the simulation-based validation of third infections. </li> <li><code>3_posterior_90_null_correctdata.RData</code> - posterior samples from the MCMC fitting procedure (as used in the manuscript) when not considering a second lambda parameter (to third infections)</li> <li><code>3_posterior_90_null_l2_correctdata.RData</code> - posterior samples from the MCMC fitting procedure (as used in the manuscript) when considering a second lambda parameter (to third infections)</li> <li><code>3_sim_90_null_correctdata.RDS</code> - simulation results when not considering a second lambda parameter for third infections (as used in the manuscript)</li> <li><code>3_sim_90_null_l2_correctdata.RDS</code> - simulation results when considering a second lambda parameter for third infections (as used in the manuscript)</li> </ul> <p> </p>
Proteomic profiling of survivors of SARS-CoV-2-induced ARDS
<p>Around 80% of patients who develop acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 infection experience persistent lung dysfunction. The molecular factors that mediate pulmonary sequelae and recovery are unknown.<strong> </strong>In this context, we sought to comprehensively characterize the proteomic determinants of pulmonary diffusion impairment.<strong> </strong></p> <p>This was a prospective cohort study including eighty-seven SARS-CoV-2–induced ARDS survivors. A complete pulmonary function evaluation and chest computed tomography (CT) were performed 3 months after hospital discharge. Proteomic profiling (364 proteins) was performed in plasma samples using proximity extension assay (PEA) technology. Partial least squares-discriminant analysis (PLS-DA) and random forest (RF) methods were used to assess predictor importance.</p> <p>Thirty percent of patients presented moderate to severe impairment of lung diffusing capacity (D<sub>LCO</sub><60% predicted). In the univariate analysis, fifteen proteins showed high concentrations in patients with D<sub>LCO</sub><60% [false discovery rate (FDR)<0.05]. Pleiotrophin (PTN) displayed the highest differences: fold change=2.22 and FDR=0.001. Differentially detected proteins showed an inverse and independent dose–response relationship with D<sub>LCO</sub>. The multivariable approaches clustered proteins according to the severity of diffusion impairment. Clusters were composed of host mediators of cell proliferation and differentiation, tissue remodeling, angiogenesis, coagulation, inflammation, immune response and fibrosis signaling.</p> <p>In survivors of SARS-CoV-2–induced ARDS, lung diffusion impairment is associated with specific circulating factors implicated in multiple injury and repair mechanisms. The host protein signatures allow a better understanding of pulmonary sequelae and may constitute therapeutic targets and biomarkers. The long-term biological and clinical significance of these observations requires further investigation.</p>
Transcriptome of Peromyscus leucopus lungs infected with SARS-CoV-2
<p><em>Peromyscus leucopus</em> is a reservoir for numerous zoonoses and one of the most abundant mammals in North America. Since they live near humans we are interested in the possibility of SARS-CoV-2 infection in this animal model from a zoonoses standpoint. The experimental design for the first trial involves using adult male and female <em>P. leucopus</em> LL stock. Animals were dosed with nasal inhalation of either tissue culture medium (DMEM) alone (controls) or alpha variant, WA1 strain of SARS-CoV-2 virus. We dosed 8 animals with a virus (titer 2x104) and 6 with DMEM alone. Animals were euthanized at either 3 or 6 days post-infection. For a second trial, <em>P. leucopus</em> animals were 1-3 years old and we had 3 groups: control animals with nasal inhalation of media, control animals with nasal inhalation of the heat-treated virus, and infected animals. Each group has 4 animals euthanized on 3- or 6-days post-infection (DPI). Lung tissue was used for RNA isolation and further sequencing to obtain 40 x 106 PE150 reads.</p>
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
ClinicalTrials.gov study NCT04371471. IPD Sharing: YES. Countries: 1. Publications: 7.
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
ClinicalTrials.gov study NCT04889209. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
ClinicalTrials.gov study NCT05877508. IPD Sharing: NO. Countries: 1. Publications: 1.
RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
ClinicalTrials.gov study NCT04700163. IPD Sharing: NO. Countries: 1. Publications: 5.
Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
ClinicalTrials.gov study NCT04402970. IPD Sharing: NO. Countries: 1. Publications: 6.
COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children
ClinicalTrials.gov study NCT04448717. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.
Singapore SARS-CoV-2 Human Challenge Study
ClinicalTrials.gov study NCT06654973. IPD Sharing: NO. Countries: 1. Publications: 2.
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
ClinicalTrials.gov study NCT04671017. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
ClinicalTrials.gov study NCT04602000. IPD Sharing: NO. Countries: 1. Publications: 4.
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
ClinicalTrials.gov study NCT04405739. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
ClinicalTrials.gov study NCT04523571. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
ClinicalTrials.gov study NCT04614948. IPD Sharing: YES. Countries: 10. Publications: 1.
Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
ClinicalTrials.gov study NCT04427280. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
ClinicalTrials.gov study NCT04344600. IPD Sharing: NO. Countries: 1. Publications: 4.
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
ClinicalTrials.gov study NCT04513158. IPD Sharing: NO. Countries: 1. Publications: 38.
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
ClinicalTrials.gov study NCT04375397. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.